RCM
VRDN icon

RA Capital Management’s Viridian Therapeutics VRDN Stock Holding History

RA Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,007,946
Closed -$30.8M – 70
2023
Q3 		$30.8M Hold
2,007,946
– – 0.61% 41
2023
Q2 		$47.8M Hold
2,007,946
– – 0.9% 32
2023
Q1 		$51.1M Buy
2,007,946
+1,127,946
+128% +$36.2M 1.16% 28
2022
Q4 		$25.7M Hold
880,000
– – 0.52% 43
2022
Q3 		$18M Buy
+880,000
New +$15.8M 0.39% 53
2021
Q4 		– Sell
-1,034
Closed -$17K – 102
2021
Q3 		$17K Sell
1,034
-311,294
-100% -$4.57M ﹤0.01% 95
2021
Q2 		$5.71M Hold
312,328
– – 0.09% 85
2021
Q1 		$5.22M Sell
312,328
-139,604
-31% -$2.61M 0.08% 79
2020
Q4 		$7.43M Buy
+451,932
New +$6.81M 0.1% 77

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RA Capital Management's VRDN Position: Q4 2023 in Review

RA Capital Management sold out of Viridian Therapeutics (VRDN) in Q4 2023, closing a stake of 2,007,946 shares — an estimated $30.8M sold.

RA Capital Management first reported a position in VRDN in Q4 2020 and held it in 9 quarters. The position peaked at $51.1M in Q1 2023. 132 funds tracked by Wall St. Rank hold VRDN as of Q4 2023.

  • RA Capital Management reported no remaining Viridian Therapeutics position as of Q4 2023 after selling out during the quarter.
  • RA Capital Management sold 2,007,946 Viridian Therapeutics shares in Q4 2023, an estimated $30.8M.
  • RA Capital Management first reported a position in Viridian Therapeutics in Q4 2020 and held it in 9 quarters.
  • RA Capital Management's Viridian Therapeutics position peaked at $51.1M in Q1 2023.
  • 132 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2023.

Based on RA Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.